about
High fat diet subverts hepatocellular iron uptake determining dysmetabolic iron overloadNonalcoholic fatty liver disease and vascular disease: state-of-the-art.Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver diseaseIncreased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease.Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development.PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease.PNPLA3 I148M polymorphism, clinical presentation, and survival in patients with hepatocellular carcinomaRisk of obstructive sleep apnea with daytime sleepiness is associated with liver damage in non-morbidly obese patients with nonalcoholic fatty liver disease.The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis.Treatment choices for people infected with HCV.Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis.Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease.Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease.The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease.CYBRD1 as a modifier gene that modulates iron phenotype in HFE p.C282Y homozygous patients.A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia.Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study.Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up.Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study.Procoagulant imbalance in patients with non-alcoholic fatty liver disease.A promoter polymorphism in the liver-specific fatty acid transport protein 5 is associated with features of the metabolic syndrome and steatosis.Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma.A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype.Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis.Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon.Hemochromatosis in Italy in the last 30 years: role of genetic and acquired factors.HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease.Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis.Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infection.Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis.Mutations in the HFE gene and their interaction with exogenous risk factors in hepatocellular carcinoma.Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease.What is the contribution of differences in three measures of tumor necrosis factor-alpha activity to insulin resistance in healthy volunteers?Cytotoxic T-lymphocyte antigen-4 A49G polymorphism is associated with susceptibility to and severity of alcoholic liver disease in Italian patients.Prevalence of hepatitis C virus infection in porphyria cutanea tarda.Harmful and Beneficial Effects of Anti-coagulants in Patients With Cirrhosis and Portal Vein Thrombosis.Mortality risk according to different clinical characteristics of first episode of liver decompensation in cirrhotic patients: a nationwide, prospective, 3-year follow-up study in Italy.Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.TNFalpha genotype affects TNFalpha release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis.
P50
Q27316857-BFF52644-8E4D-4FEC-ACE3-5A5AEE26008FQ27692035-44353CFE-53CE-423D-A417-8CFF78A39A19Q28291518-D645721B-3EA6-4EAB-9D44-6A9456199FA8Q32075982-178E294D-73B1-484B-BF1D-3C6C56E7BAD8Q34535655-C93F611B-4C2D-4689-9A0F-980BE4F71EE1Q34998991-B1096A7A-D655-4B3F-A6F3-49D34B68ACD9Q35025215-612E8E4F-D39F-4746-9777-CBCE028F59F4Q35157250-3FFB4FA8-0E0D-4011-A863-FE609FA94EA4Q35444526-B2B70C2E-1090-4D36-BB45-37C1521DFA0CQ35741665-D572E599-52C6-4E3C-AEF2-7EC62D1227FCQ36031314-42D6FDCD-FF42-4435-BBE2-4325997BB6E7Q36116709-2EBBA808-37F7-42AF-A32E-4DF84528C61BQ36132807-8F959B5C-5465-48FA-B72B-D210353C6EAAQ36373567-9C49713E-15A0-40A9-AC86-3B7084BC3865Q36662023-555B6A33-9F23-4C6A-A463-E97BCF6E16EEQ37654465-E82310C8-65EB-4EA9-88FC-147051B1C97DQ38758257-FC61D8A9-A10F-454B-8016-5970CFB279D7Q38843749-CA549C85-9B6A-42D5-9BE2-1CD56ED54C1BQ40069136-B1F497E9-0E1F-410A-8188-D02F82C7AAF0Q40229390-453D4274-8160-484E-9971-282294192DEFQ42229743-EBBE5450-0BF6-4B5F-8C05-8A054130A8EBQ42859479-35D1A55F-D8D7-4367-9563-F35EA7CDAC06Q42992460-2B0CF0DA-9633-42F1-B80A-736F3DF45AADQ42998816-0080E868-6226-42D3-AAFF-24DF533C844AQ43039405-1FAE9194-A25F-4D83-9E53-F4B1BEFFFAAFQ43049090-0C20BCAD-7CB2-42E8-8BA0-0FBB3E1250DFQ43184153-20980DB8-D032-49AA-9695-7F74EE1B0261Q43237367-1914EF4D-2FB8-4C3B-8474-5233E31D2932Q43533946-7EE66247-D017-47D2-B54D-B76DC42ABCBFQ43570543-F023C44A-A79A-4C98-B843-76F2FC7D27C8Q43627712-D3E19BC9-D741-4A11-85A5-D4EC6FC161B2Q43703948-571F3B70-4FCA-44DB-8112-5087E9A46D6CQ44635553-9EBEB111-4EB7-4B50-AB8C-D8D1787B75A9Q44688786-70E8A9F7-0FAE-4017-9E9C-BF574E80B588Q44945308-3B16890C-94D4-41E2-B658-778095D87DD3Q45721816-17908067-3A03-40F4-91F1-86C6D22AE4C3Q45873561-01A53690-2447-45E9-9424-554C49BE7568Q46058435-E67BC6ED-BBA3-4C77-8E7A-E5D7DB2FC52BQ46408077-139763CD-0525-4D3E-B640-B5B9E57BDCB2Q46688143-7EBC6ED1-FD0A-49D0-95A8-6492693E3060
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Anna L. Fracanzani
@ast
Anna L. Fracanzani
@en
Anna L. Fracanzani
@es
Anna L. Fracanzani
@nl
type
label
Anna L. Fracanzani
@ast
Anna L. Fracanzani
@en
Anna L. Fracanzani
@es
Anna L. Fracanzani
@nl
prefLabel
Anna L. Fracanzani
@ast
Anna L. Fracanzani
@en
Anna L. Fracanzani
@es
Anna L. Fracanzani
@nl
P106
P1153
7003933583
P21
P31
P496
0000-0001-5918-0171